France · Biotechnology startup
France · Abivax
Abivax develops medicines that alter the body's natural immune system mechanisms.
Funding reportedLast round: Post ipo debt
What company datasets say Abivax raised
Funding, as reported
Reported in all376.2Min the source's currency
Rounds6
Last roundPost ipo debt
Last round dateAug 2023
Investors listed14
Founders and team
From Abivax's own website: 4 on the team.
- Hema KeshavaSenior Vice President, Finance
- Camilla SoenderbyCFO of Rapport Therapeutics
- Troy IgnelziCFO of Rapport Therapeutics
- Ida HatoumTeam
Biotechnology in France
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Abivax in front of investors. Or tell us what we have wrong.